Back

Tolerability of continued treatment with ATTR depleter ALXN2220 in the open-label extension of Phase 1 study NI006-101

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure management in specific populations Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Olivier Lairez

University of Toulouse, Toulouse (France)

9 More presentations in this session

Presentation thumbnail
Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population
Doctor J. Noiri (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Phenotypes of heart failure with preserved ejection fraction and effect of sodium-glucose cotransporter 2 inhibitors treatment
Doctor A. Sezaki (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
The relevant role of frailty in patients with transthyretin amyloidosis cardiomyopathy
Doctor B. Dal Passo (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
Role of comorbidities and weight variations in the survival of diabetic patients with heart failure
Professor O. Hanon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Angiotensin receptor-neprilysin inhibitor-based therapy among adult heart failure patients with below normal systemic ventricular ejection fraction and complex congenital heart disease
Doctor D. Dela Cruz (Metro Manila, PH)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure management in specific populations

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Initial safety of targeted immune activation with the amyloid depleter ALXN2220
thumbnail
Congress Presentation
Evolution over time of cardiac biomarkers, electrocardiographic and echocardiographic features in a large cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis
thumbnail
Congress Presentation
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources